JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

Jazz Pharmaceuticals’ Ziihera received FDA approval for first-line HER2-positive gastric/GE junction adenocarcinoma (GEA), moving the therapy into earlier-line treatment. The approval supports potential market expansion and is backed by reported progression-free and overall survival benefits. Overall, the regulatory milestone is a meaningful positive catalyst for revenue expectations and equity sentiment.